Erasca shares surge 11.44% after-hours after securing 2043 U.S. patent for ERAS-0015 and disclosing 2026 Phase 1 data milestones.

Erasca surged 11.44% in after-hours trading following the release of third-quarter business updates and patent developments. The stock’s rally was driven by the announcement of a U.S. composition-of-matter patent for its pan-RAS molecular glue ERAS-0015, extending exclusivity through 2043, and the promotion of Robert Shoemaker, Ph.D., to chief scientific officer, reinforcing leadership. Additionally, the company highlighted a robust $362.4 million cash position, sufficient to fund operations through H2 2028, and provided clarity on 2026 Phase 1 monotherapy data readouts for both ERAS-0015 and ERAS-4001. These developments underscored progress in its RAS-targeting pipeline, reduced near-term dilution risks, and positioned the company for key clinical milestones, collectively fueling investor optimism.